

European Directorate for the Quality of Medicines & HealthCare

Council of Europe



European Directorate | Direction européen for the Quality | de la qualité of Medicines | du médicament & HealthCare | & soins de santé



**Opening Session - Welcome Addresses** 

26-27 March 2025



Petra Doerr, EDQM, Council of Europe
Laurent Mallet, EDQM, Council of Europe
Stefaan van der Spiegel, DG SANTE, European Commission

26-27 March 2025







European
Directorate for
the Quality of
Medicines &
HealthCare





# Council of Europe

**±** Established in **1949** 

**46** member states

★ Based in **Strasbourg** 

★ Three main values: human rights, democracy and the rule of law





Committee of Ministers



Parliamentary Assembly



Congress of Local and Regional authorities



European Court of Human Rights



Commissioner of Human Rights



Conference of INGOs





## **European Committee on Blood Transfusion (CD-P-TS)**







Developing legal instruments, technical standards, policies

Monitoring data and best practices




edom C



Operational activities supporting
SoHO establishments in
implementing CoE standards
& EU legislation





Mutual assistance

Protection of donors & recipients






## **EDQM**

- ★ Founded in 1964
- ★ Partial Agreement (39 members & the EU + 34 observers)
- ★ Contributes to public health and access to good quality medicines and healthcare in Europe

★ Wide scope of activities



## Our vision

Together for better health, for all

## Our mission

To contribute to public health protection by engaging with an international community of experts and stakeholders





# Four policy areas & a wide portfolio of activities



# Medicinal products

Official standards for manufacture and quality control of pharmaceuticals

European Pharmacopoeia
(documentary & reference standards), Biological

Standardisation Programme

Certificates of suitability confirming compliance with European Pharmacopoeia and GMP inspections

Certification of suitability

Control of medicines

Network of Official Medicines

Control Laboratories (OMCL)



# Pharmaceutical care

Policies & model approaches for the safe use of medicines

Co-operation to combat falsification of medical products



# Consumer health

Safety standards for cosmetics, tattoos and food contact materials

Control of cosmetics
Network of Official
Cosmetics Control
Laboratories (OCCL)



# Substances of human origin

Quality & safety standards

Data collection

Improving quality systems / capacity building of blood and tissues & cells establishments






## CD-P-TS **Blood transfusion**


## Main objective



Ensures quality and safety of blood and blood components and application of ethical principles







### **Activities**

## **Standard setting**

- Resolutions & recommendations Technical standards: Blood Guide





Blood Guide referred to in the new **EU SoHO legislation** 

Monitoring data and practices: annual data collection on use of SoHO and vigilance





### **Capacity-building activities**

- Blood Quality Management (B-QM)
  Blood Proficiency Testing Scheme (B-PTS)

## **PUBLIC HEALTH IMPACT**



Protects donors and patients






# EDQM and EU today: a strategic and agile co-operation

### The EDQM, a regulatory and technical partner of the EU

- 60 years of collaboration in the field of medicinal products
- 15 years of collaboration in the field of SoHO



## The Scientific Committee

Johanna Castrén

Vincenzo De Angelis

Fabio Candura

Piotr Radziwon

**Stephen Thomas** 



Thank you for your attention.

26-27 March 2025









European Directorate for the Quality of Medicines & HealthCare

Council of Europe



European Directorate | Direction européen for the Quality | de la qualité of Medicines | du médicament & HealthCare | & soins de santé





European Directorate for the Quality of Medicines & HealthCare

Council of Europe



European Directorate | Direction européen for the Quality | de la qualité of Medicines | du médicament & HealthCare | & soins de santé



Setting the scene - Objectives of the meeting

26-27 March 2025







Johanna Castrén, Chair of the European Committee on Blood Transfusion, Council of Europe

Richard Forde, EDQM, Council of Europe

26-27 March 2025





## **History / Starting Point** Plasma Supply Management Symposium 2019

- Jointly organised by EU Commission and EDQM (TS093 Plasma **Working Group)**
- Discuss obstacles in Europe to strategic independence of plasma for fractionation in Europe
- Discuss donor protection safety, selection and management
- Presenting evidence-based data for revision of Blood Guide (20th Ed) plasmapheresis donors
- Recommendations to stakeholders

**EU Commission** EDQM/CD-P-TS Member States National **Competent Authorities Blood Establishments** 

**Professional Societies** 

Plasma Fractionators Patient Associations **Donor Associations** 



https://www.edgm.eu/en/plasma-supply-management





PLASMA SUPPLY MANAGEMENT

## **Current Landscape**

#### **CD-P-TS working party**

6.3. TS119 - Anti D Immunoglobulin

A kick off meeting of the working group on Anti-D Immunoglobulin was scheduled for 25th January 2023. An extended working group has been convened, including members nominated through the CD-P-TS and representatives from IPFA and PPTA and other Industry representatives.

TS119 aims to gain attention and a call for action on the growing shortage and lack of self-sufficiency in the supply of anti-D plasma. The working group will focus on the international cooperation on anti-D plasma collection, immunisation of donors; issues relating to the manufacture and access to polyclonal anti-D immunoglobulins and will explore the state of play in the development of alternative or complementary products to polyclonal anti-D immunoglobulins.





New EU rules on substances of human origin Reform of the EU pharmaceutical legislation
















medicinal products in the future of Europe

PLASMA PROTEIN

THERAPEUTICS

Securing commitment and control for the supply of plasma derivatives for public health systems. I: A short review of the global landscape

Leni von Borndorff<sup>1</sup> | Albert Farrugia 12 | Fabio Candura | Peter O'Leary<sup>4</sup> |

Delveration	Spet
95.1	Criss bituations - The impact on the plasma medicine gettent sharn Asulyys and Recommendations Stomatic Evaluation Plans
89.1	Fluoria Donor recruitment and retarrisis - Current Practice (Analysis Report)
10.2	Plasma Dinner recognisment and retention strategies: - Afficiency evaluation (Recommendations Report and Founder Plans)
000	Setting up a Plasma Centre: Practical tools (Plasma Collection Recommendations and Support Tool)
81.2	The plasma pureray from collection to transport to fractionation - Recommendations for trapsoversent
00.3	Opportunities to monete Plasma columns. Seconded and use plasmapheress. Analysis and Recommendations.
20.0	Fair world experience, impresentation of the reconstructations to his recent Pleate volumes.
20.6	Force on quality. An assistment of plantal down characteristics, menungiplosin, and Talai Protein in downed planta
	Member State steps on the European path to Streege independence for Pleana-Medicines: A Position













**IPFA/EBA Symposium on** 









## **Needs and Considerations - Continuity**

### **Collaboration and Coordination**

- Data
- Tools
- Benchmarking
- Networking

### **Role of the CD-P-TS**

- > The Blood Guide revision
- Data Collection and Reporting
- Plasma-specific Working Parties, Events, Symposia



### Stakeholder Event

Plasma Supply Continuity 26-27 March 2025, Strasbourg

www.edqm.eu/en/plasma-supply-continuity





## **Objectives**

★ Acknowledge the significant efforts and progress that has been made across European countries in increasing and improving the supply of plasma and PDMP and recognizing the dedication and commitment of all who continue to support these efforts



Plasma Supply Continuity 26-27 March 2025, Strasbourg

www.edqm.eu/en/plasma-supply-continuity

- ★ Opportunity to exchange on strategies to improve and increase the safe collection and adequate supply of plasma and plasma-derived medicinal products (PDMP), addressing current challenges, key needs and actions
- Identify areas of priority and challenges
  - Action plans key areas for political support and investment
  - Tools and toolkits to develop
  - Next steps for concrete collaboration and coordination



